Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages

Metagenomi, Inc. (NASDAQ:MGX) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.00.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a research report on Monday, December 22nd.

Metagenomi Stock Performance

Shares of MGX opened at $1.52 on Monday. The stock has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $1.94. Metagenomi has a 52-week low of $1.23 and a 52-week high of $3.95. The firm has a market capitalization of $57.08 million, a PE ratio of -0.63 and a beta of 0.50.

Institutional Trading of Metagenomi

A number of institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its holdings in shares of Metagenomi by 1,840.0% during the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after buying an additional 14,389 shares in the last quarter. Bank of America Corp DE lifted its stake in Metagenomi by 508.5% in the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after acquiring an additional 15,682 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Metagenomi by 53.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock worth $32,000 after acquiring an additional 7,458 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Metagenomi during the 3rd quarter worth approximately $64,000. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Metagenomi in the fourth quarter valued at approximately $53,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.